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A B S T R A C T
Background: The development of candidate gene approaches to enable molecular diagnosis of
hypertrophic cardiomyopathy (HCM) has required extensive and prolonged efforts. Whole exome
sequencing (WES) technologies have already accelerated genetic studies of Mendelian disorders,
yielding approximately 30% diagnostic success. As a result, there is great interest in extending the use of
WES to any of Mendelian diseases. This study investigated the potential of WES for molecular diagnosis
of HCM.
Methods: WES was performed on seven relatives from a large HCM family with a clear HCM phenotype
(ﬁve clinically affected and two unaffected) in the Kanazawa University Hypertrophic Cardiomyopathy
Registry. Serial bioinformatics ﬁltering methods as well as using combined annotation dependent
depletion (CADD) score and high heart expression (HHE) gene data were applied to detect the causative
variant. Moreover, additional carriers of the variant were investigated in the HCM registry, and clinical
characteristics harboring the variant were collected and evaluated.
Results: WES detected 60020 rare variants in the large HCM family. Of those, 3439 were missense,
nonsense, splice-site, or frameshift variants. After genotype–phenotype matching, 13 putative variants
remained. Using CADD score and HHE gene data, the number of candidates was reduced to one, a variant in
the myosin essential light chain (MYL3, NM_000258.2:c.281G>A, p.Arg94His) that was shared by the ﬁve
affected subjects. Additional screening of the HCM registry (n = 600) identiﬁed two more subjects with this
variant. Serial assessments of the variant carriers revealed the following phenotypic characteristics: (1)
disease-penetrance of 88%; (2) all clinically affected carriers exhibited asymmetric septal hypertrophy with
a substantial maximum left ventricular wall thickness of 18  3 mm without any obstruction.
Conclusions: WES combined with CADD score and HHE gene data may be useful even in HCM.
Furthermore, the MYL3 Arg94His variant was associated with high disease penetrance and substantial
interventricular septal hypertrophy.
 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Hypertrophic cardiomyopathy (HCM) is a genetically heteroge-
neous myocardial disorder with various morphological, functional,
and clinical characteristics [1–5]. Familial HCM, which has a
prevalence of up to 1 in 500 individuals, is one of the most common
autosomal dominant inherited disorders [6]. Myosin heavy chain
(MYH7, OMIM#: 160760), myosin binding protein C (MYBPC3,
OMIM#: 600958), troponin T (TNNT2, OMIM#: 191045), tropomy-
osin (TPM1, OMIM#: 191010), and troponin I (TNNI3, OMIM#:
191044) have been reported to be the main causal genes [2–4,7–
11]. To date, candidate-gene approaches using traditional Sanger
sequencing have enabled the identiﬁcation of causative variants in
approximately 50% of HCM patients [8]. However, because these
techniques are onerous and time-consuming, motivating the
researchers to perform target re-sequencing with next generation
sequencing (NGS) as well as whole exome sequencing (WES) which
is reported to have a success rate of nearly 30% in identifying disease-
causing variants in patients whose causal variants have not been
detected [12]. Although several other reports have demonstrated the
efﬁcacy of target re-sequencing for sporadic HCM patients [13,14], it
remains unclear whether WES enables comprehensive identiﬁca-
tion of causative variants in an exome-wide manner. This study
investigated the effectiveness of WES with bioinformatics for
molecular diagnosis for HCM.
Materials and methods
Study population
All subjects were enrolled through the Kanazawa University
Hypertrophic Cardiomyopathy Registry in Kanazawa, Japan. The
largest HCM family in the registry, whose causative variant had not
been detected by traditional direct sequencing, was ﬁrst investigat-
ed in this study. HCM was diagnosed according to the 2011 version of
the guideline of the American College of Cardiology Foundation/
American Heart Association [1]. In brief, subjects with a maximal left
ventricular wall 13 mm (involving asymmetric septal hypertro-
phy) without extra-cardiac or metabolic ﬁndings based on
echocardiography were diagnosed with HCM. Individuals were
classiﬁed as HCM-affected in the case diagnosed with HCM, or HCM-
unaffected in the case of either a non-HCM phenotype or known
diseases such as hypertensive heart disease. Detailed clinical data,
including family history, age, and symptoms at evaluation, presence
of hypertension, physical examination, New York Heart Association
(NYHA) classiﬁcation, electrocardiogram (ECG) and echocardio-
graphic ﬁndings were collected for each subject. Hypertrophic
obstructive cardiomyopathy (HOCM) was deﬁned as HCM with left
ventricular outﬂow tract (LVOT) obstruction and a peak instanta-
neous LVOT pressure gradient of >30 mmHg. Maximum left
ventricular wall thickness (MWT) was deﬁned as the greatest
thickness within the chamber. Other echocardiographic parameters
were evaluated using the recommendation of the American Society
of Echocardiography [15]. Hypertension was deﬁned as when a
patient’s systolic blood pressure (BP) was 140 mmHg and/or its
diastolic BP was 90 mmHg. Pathological Q waves were deﬁned as
follows based on previous studies: Q wave >1/4 of the ensuing R
wave in depth and/or >40 ms in duration in at least two leads except
aVR [16]. T waves >10 mm in depth in any leads were deﬁned as
giant negative T waves (GNTW) [17]. The Ethics Committee for
Medical Research at our institution approved the study protocol, and
all subjects provided written informed consent.
Exome sequencing
Genomic DNA was isolated from peripheral white blood cells of
all subjects using a standard DNA extraction protocol. DNA waspooled, selected size, ligated to sequencing adapters, and ampliﬁed
to enrich for targets to be sequenced by the Agilent SureSelectXT
Target Enrichment System (Agilent Technologies Inc., Santa Clara,
CA, USA). Exome capture was performed with the Agilent
SureSelectXT Human All Exon 50 Mb Kit (Agilent Technologies
Inc.). Exome enriched products were sequenced using the Illumina
HiSeq 2000 by Takara Bio Inc., Shiga, Japan. One sample was
sequenced per lane to obtain an average theoretical depth of 80x,
using 2x100 bp sequencing.
Bioinformatics
For the samples, paired-end reads were aligned using the
Burrows-Wheeler Aligner on the human reference genome build
hg19 using quality score calibration, soft clipping, and adapter
trimming. Following the exclusion of PCR duplicate reads using the
Picard, insertions/deletions and single-nucleotide polymorphisms
(SNP) were called using the Genome Analysis Toolkit (GATK)
[18,19]. Variants (SNP/indels) were ﬁltered on the basis of the
Phred scaled genotype quality score. Re-alignment was performed
and the calling algorithm merged the output of GATK Uniﬁed
Genotyper. All samples were annotated using SnpEff [20] (version
3.6) to classify variants (e.g. missense, stop gain/loss, splice-site
variant, synonymous, intronic, insertions/deletions).
In addition to the standard variant quality controls, six
independent ﬁlters were applied to facilitate detection of causal
variants among the enrolled HCM families. Variants were ﬁltered
by: (1) minor allele frequency (MAF) >1% in Asian population; (2)
benign, as predicted by SnpEff; (3) genotype–phenotype un-
matched under the assumption of complete penetrance without
phenocopies; (4) registered in the SNP Database (dbSNP137); (5)
combined annotation dependent depletion (CADD) score <10; and
(6) low heart expression of the genes, less than the top quartile.
The frequency ﬁlter adopted the allele frequency estimates
from the Asian cohort of the 1000 Genomes Project database [21],
and we used a MAF 1% as the cut-off. Genotype–phenotype
matching was deﬁned as narrowing the variants at which affected
subjects had 1 alternative allele(s) and unaffected subjects had
no alternative allele. As a functional ﬁltering method, variants not
registered in NCBI dbSNP137 were considered to be candidate
variants. Prediction of in silico pathogenicity for novel missense
variants was performed using the CADD prediction software
(version 1.0), which objectively integrates many diverse annota-
tions into a single measure (C-score) for each variant [22]. A variant
was predicted to be pathogenic if the scaled C-score calculated by
the software was above 10, a score indicative of the variant being
within the top 10% of deleteriousness substitutions. Candidate
variants were evaluated if the gene associated with each variant
was directly involved in the myocardium or worsening cardiac
function by using the high heart expression (HHE) gene data as
previously reported [23]. In brief, HHE genes were deﬁned as the
top quartile [>40 reads per million mapped reads (rpm)] of 16,599
human-mouse orthologous gene expressions generated by RNA
sequencing data of mice hearts at embryonic day 14.5.
After the evaluation, Sanger sequencing method was performed
to conﬁrm the putative variant identiﬁed by the bioinformatics
analysis in the tested subjects and other relatives.
Additional screening for HCM registry
In addition, restriction fragment length polymorphism (RFLP)
was performed on HCM probands listed in our registry to identify
other subjects harboring the variant. In brief, restriction enzyme
(Van91I) was added to each DNA sample and incubated for 3 h,
which allowed the enzyme to cut at the recognition site (in this
case, the myosin essential light chain [(MYL3, OMIM#: 160790),
Table 1
Clinical features of carriers harboring the MYL3 (Arg94His) variant in HCM-F18 and HCM-F189 families.
Pedigree ID Gender Agea HT LVOT
obstruction
Symptoms NYHA ECG ﬁndings QW GNTW LAD MWT IVS PW LVDd LVDs LVEF
HCM-F18
III:3 Male 74 – – – I 18AV-block, CLBBB –  47 19 19 8 55 33 61
III:6 (proband) Female 60 – – – I AF, LVH –  61 20 20 10 38 25 64
III:9 Female 58 – – – I LVH –  28 23 23 11 38 23 71
III:12 Male 51 – – Syncope I 18AV-block, NSVT –  53 18 18 11 48 33 59
IV:6 Female 37 – – – I – –  18 10 10 9 38 23 65
IV:11 Female 24 – – – I IRBBB –  30 15 15 11 39 21 72
HCM-F189
II:2 Male 75 – – – I LVH – + 35 18 18 12 43 26 65
III:5 Male 41 – – – I LVH –  28 13 13 10 43 30 52
AF, atrial ﬁbrillation; ASH, asymmetric septal hypertrophy; CLBBB, complete left bundle branch block; ECG, echocardiography; GNTW, giant negative T wave; HT,
hypertension; IRBBB, incomplete right bundle branch block; IVS, interventricular septum diameter; LAD, left atrial dimension; LVDd, left ventricular diastolic diameter;
LVDs, left ventricular systolic diameter; LVEF, left ventricular ejection fraction; LVH, left ventricular hypertrophy; LVOT, left ventricular outﬂow tract; MWT, max wall
thickness; NSVT, non-sustained ventricular tachycardia; NYHA, New York Heart Association heart failure classiﬁcation; PW, posterior wall diameter; QW, Q wave.
a Age at examination.
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separated by size using gel electrophoresis to allow conﬁrmation of
cutting of the sample DNAs. To investigate the ancestral origin of
the variant, haplotype analysis was performed by using six
microsatellite markers (short tandem repeats [(CA)n: D3S3687,
D3S3678, D3S3647, D3S3582, D3S3640, D3S1568] ﬂanking the
variant gene) [24,25]. Clinical characteristics of variant carriers
were documented for phenotype evaluation of the variant.
Results
Characteristics of HCM-F18 family members
Clinical characteristics of HCM-F18 family members are shown
in Table 1, and a representative case (III:6, proband) is presented in
Fig. 1. The subject was referred to our hospital because of an
abnormal ECG ﬁnding detected by a local hospital. ECG showed
atrial ﬁbrillation with left ventricular hypertrophy pattern, chest
X-rays displayed an increase in cardiothoracic ratio, and echocar-
diography revealed an apparent interventricular septal hypertro-
phy without LVOT obstruction. After excluding other cardiac
diseases, the subject was diagnosed with HCM.
Although the HCM-F18 proband and her family members
had been clinically observed for years, traditional Sanger
sequencing failed to identify the apparent causative variants.
The HCM-affected family members had a typical clinical
phenotype consistent with HCM, exhibiting interventricularFig. 1. A representative case (proband) in hypertrophic cardiomyopathy (HCM)-F18 famil
chest X-ray; (B) electrocardiogram; (C) echocardiography of longitudinal views. Chest X
showed atrial ﬁbrillation with left ventricular hypertrophy pattern; and echocardiogr
hypertrophy without left ventricular outﬂow tract obstruction (arrow head). Ao, aorta;septal hypertrophy and asymmetric septal hypertrophy. The
affected subjects comprised two males and three females with
an age range at enrollment of between 24 and 74 years. The
HCM-unaffected subjects were a 67-year-old female diagnosed
with hypertensive heart disease and a 48-year-old female
without any cardiac disease.
Exome sequencing and bioinformatics analyses
DNA samples from seven members of the HCM-F18 family, ﬁve
clinically HCM-affected subjects, and two unaffected subjects were
analyzed using WES (Fig. 2) followed by bioinformatics ﬁltering
methods (Table 2). The mean sequencing depth for the seven
subjects was 56.1x, 60.0x, 54.8x, 58.7x, 58.2x, 63.7x, and 66.0x per
base across the whole exome, for samples III:2 (unaffected), III:3
(affected), III:6 (affected), III:9 (affected), III:12 (affected), IV:7
(unaffected), and IV:11 (affected), respectively. Percentages of on-
target reads were 78.6% (III:2), 78.0% (III:3), 77.3% (III:6), 79.4%
(III:9), 77.2% (III:12), 78.7% (IV:7), and 77.0% (IV:11), respectively,
while coverage rates of target coding lesions (20x) were 89.3%
(III:2), 90.1% (III:3), 89.0% (III:6), 90.8% (III:9), 89.7% (III:12), 91.7%
(IV:7), and 92.0% (IV:11), respectively.
Subsequent to WES, bioinformatics analysis and genotype–
phenotype matching following exome sequencing were performed
for family HCM-F18 to identify causative variants found in all ﬁve
HCM-affected subjects but not in the two unaffected subjects
(Table 2). The number of aligned variants in the seven subjects withy. Clinical images of the proband (III:6 in Table 1) in HCM-F18 family are shown: (A)
-ray showed that the cardiothoracic ratio was increased (61%); electrocardiogram
aphy presented normal ejection fraction and an apparent interventricular septal
 LA, left atrium; LV, left ventricle; RV, right ventricle.
Fig. 2. Pedigrees of families: (A) hypertrophic cardiomyopathy (HCM)-F18 and (B) HCM-F189. The pedigrees of HCM families with the myosin essential light chain (MYL3)
variant (Arg94His) are shown. Arrows indicate probands. Squares represent male subjects; circles represent female subjects. Diagonal lines mark deceased individuals. Solid
symbols denote HCM. Open symbols represent unaffected individuals or individuals with no data available for analysis. Gray symbols represent obligate carriers. Plus ‘‘(+)’’
and minus ‘‘()’’ signs indicate presence or absence of the Arg94His variant conﬁrmed by direct sequencing, respectively. Encircled numbers indicate subjects investigated by
whole exome sequencing. Haplotypes (the number of [CA]n repeat) are listed for six microsatellite markers ([1] D3S3687 – [2] D3S3678 – [3] D3S3647 – [4] D3S3582 – [MYL3]
– [5] D3S3640 – [6] D3S1568) from top to bottom. Boxed haplotypes demonstrate affected haplotypes. Affected haplotypes share same numbers of [CA]n repeat from [3]
D3S3647 to [6] D3S1568 in both families, indicating that the MYL3 Arg94His variant originated from the same ancestor.
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considered to be rare variants (MAF <1%) using the Asian cohort in
1000 Genome Project [21]. Focusing on missense, nonsense, splice-
site, and frameshift variants, 3439 variants were detected. Geno-
type–phenotype matching enabled putative variants to narrow the
number to 13. After excluding variants registered in dbSNP137, six
putative variants remained (Table 3). To evaluate these variants,
CADD prediction software was used to calculate each scaled C-score.
Five out of six variants were predicted to be damaging (scaled C-
score >10), indicating that these were potentially deleteriousTable 2
Algorithm of bioinformatics ﬁltering methods.
Total aligned variants in seven subjects 257452
After QC 243359
#
Filtering methods
MAF <1% in the 1000 Genome Project (Asian cohort) 60020
#
Missense, nonsense, splice-site or frameshift variants 3439
#
Genotype–phenotype matching 13
#
Remove dbSNP137 registered variants 6
#
CADD score >10 5
#
High heart expression gene 1
The number of variants was decreased according to each ﬁltering step. Finally,
1 variant, MYL3 c.281G>A was thought to be the causative variant.
CADD, combined annotation dependent depletion; MAF, minor allele frequen-
cy; QC, quality control; dbSNP, the Single Nucleotide Polymorphism Database.variants. Among the candidate variants, myosin essential light chain
(MYL3, c.281G>A, p.Arg94His) was the only gene that belonged to
the HHE genes and was directly associated with the myocardium
(ventricular muscle). Although this MYL3 Arg94His variant was not
listed in the NHLBI ESP exome variant server [26], the Human
Genetic Variation Database [27], or the Exome Aggregation
Consortium database [28], the variant was reported to be a possibly
damaging variant in the Human Gene Mutation Database [29]. San-
ger sequencing for the 10 HCM-F18 family members validated the
variant in all the affected subjects and resulted in the detection of
one additional variant carrier without an apparent HCM phenotype
(Figs. 2 and 3).
Phenotype evaluation of MYL3 (c.281G>A, p.Arg94His) variant
All 600 familial or sporadic HCM probands listed in the registry
were screened for the MYL3 (c.281G>A, p.Arg94His) variant by
RFLP analysis using the Van91I restriction enzyme. The Arg94His
variant was identiﬁed in one additional proband (HCM-F189) and
Sanger sequencing conﬁrmed that two additional subjects had the
MYL3 Arg94His variant (Fig. 2). Moreover, haplotype analysis of
family HCM-F18 and family HCM-F189 using six microsatellites in
the neighborhood revealed that the MYL3 Arg94His variant
originated from the same ancestor (Fig. 2).
The clinical characteristics of the eight MYL3 Arg94His variant
carriers are summarized in Table 1. Disease-penetrance was 88%,
and all clinically affected carriers exhibited asymmetrical septal
hypertrophy with a substantial maximal left ventricular wall
thickness of 18  3 mm. Left ventricular systolic dysfunction
(ejection fraction <50%) was not observed. Abnormal ECG ﬁndings
were observed in seven carriers with an apparent HCM phenotype.
Table 3
Candidate variants after ﬁltering methods in HCM-F18.
Gene Function Chr. Exon Position
(build 37)
NM # Amino
acid
SIFT PolyPhen-2 MutationTaster2 CADD
score
HHE
gene
HMGB4 High Mobility Group Box 4 1 2 34329932 145205 E47A 0.01 0.999 DC 24.5 
HHATL Hedgehog Acyltransferase-Like 3 9 42738359 20707 R341C 0 1 DC 18.7 
MYL3 Myosin Light Chain 3,
Ventricular, Skeletal
3 3 46902192 258 R94H 0.04 0.008 DC 16.63 +
NIPAL4 NIPA-Like Domain Containing 4 5 1 156887258 1172292 R39Q 0.25 0.002 Poly 19.5 
PLAU Plasminogen Activator, Urinary 10 10 75676220 1145031 R381L 0.11 0.009 Poly 9.587 
LIPM Lipase, Family member M 10 4 90574372 1128215 G184S 0.01 0.981 DC 35 
The six variants in six genes ﬁltered by bioinformatics methods are present in ﬁve HCM-affected subjects and are absent in two unaffected subjects. Of those, 5 variants
had the CADD score more than 10, and MYL3 gene was the only gene that highly expressed in mice hearts.
SIFT scores (ranges from 0 to 1) were calculated by SIFT version 5.2.2, and the SIFT score less than 0.05 was considered as deleterious. PolyPhen-2 scores (ranges from 0 to
1) were calculated by PolyPhen-2 version 2.2.2, and the PolyPhen-2 score more than 0.85 was considered as probably damaging. The six variants were also evaluated by
MutationTaster2 (classifying variants as ‘‘Disease causing’’ or ‘‘Polymorphism’’).
CADD, combined annotation dependent depletion; Chr, chromosome; DC, disease causing; HCM, hypertrophic cardiomyopathy; HHE, high heart expression; Poly,
polymorphism; PolyPhen, Polymorphism Phenotyping v2 score; Position, nucleotide position; SIFT, Sorting Intolerant From Tolerant score.
Bold highlights the causative variant.
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atrioventricular block, two had bundle branch block, and one had
atrial ﬁbrillation with an enlarged left atrium. GNTW was observed in
one subject, but pathological Q wave was not observed.
Clinical follow-up data were available for four of eight subjects.
Although they suffered from neither cardiac death nor progression
of left ventricular systolic dysfunction during >10 years follow-up,
one subject (HCM-F18; III:12) received an implantable cardiover-
ter deﬁbrillator (ICD) because of syncope with frequent non-
sustained ventricular tachycardia. Another subject (HCM-F18;
III:6) died from non-cardiac causes (postoperative infection after
an orthopedic surgery).Fig. 3. NGS read alignment and the Sanger sequencing validation in the MYL3 gene at exon
2.3. The red arrow in IGV indicates the p.Arg94His variant position in the MYL3 gene at e
affected subjects also shows the same variant at the same position.Discussion
In this study, WES was demonstrated to be an effective tool,
even in HCM. Furthermore, we determined the MYL3 Arg94His
variant was newly identiﬁed as a variant associated with high
disease penetrance and substantial degree of interventricular
septal hypertrophy for the ﬁrst time. This is the ﬁrst study to
validate the MYL3 Arg94His as a causative variant of familial HCM
using WES.
Since the application of NGS methods such as WES and target
re-sequencing for clinical genetics, the number of bioinformatics
approaches for detecting the causative variant in patients in 3. Alignment reads are visualized by the Integrative Genomics Viewer (IGV) version
xon 3 (50 ! 30 complementary strand). The red arrow in Sanger sequencing data of
A. Nomura et al. / Journal of Cardiology 67 (2016) 133–139138cardiomyopathy has gradually increased [30,31]. This is because
the traditional direct sequencing methods have only been able to
identify approximately 50% of the causative variants in patients
with cardiomyopathy [8]. Several clinical studies have demon-
strated that WES is effective for molecular diagnosis of cardiomy-
opathy [30,31], providing support for the notion that WES may be
useful in diverse ethnic settings.
In this study, two novel ﬁltering schemas were adopted to enable
causative variants to be distinguished from thousands of other
incidental variants detected via WES. The CADD C-score [22] is a
highly combined damaging score for each variant that is generated
by 63 distinct annotation tools including SIFT [32] and PolyPhen
[33]. This means that we can obtain the comprehensive damaging
scores of each candidate variant even though each annotation tool
shows discordant results. For example, the MYL3 Arg94His variant
was ﬁrst predicted as deleterious by SIFT and disease-causing by
MutationTaster2 [34], but was considered as benign by PolyPhen-2
(Table 3). However, the CADD C-score of the variant was 16.63,
clearly predicting that the MYL3 Arg94His as deleterious. Further-
more, prediction of the pathogenicity of human variants with the
CADD C-score is more accurate than that of any other in silico single
annotation tool [22]. Actually, the usefulness of CADD C-score for
detecting causative variants in patients with Tangier disease and
long QT syndrome were previously reported [35,36]. In terms of HHE
[23], Zaidi et al. demonstrated that HHE genes had a higher
frequency of protein-alternating de novo variants than genes with
low heart expression (less than top quartile) in patients with
congenital heart diseases [23]. In the present study, the combination
of the CADD scaled C-score and the heart expression-oriented
ﬁltering schema successfully narrowed down the number of
causative variants to a single variant, the MYL3 Arg94His variant,
suggesting the usefulness of this schema even in heterogeneous
diseases such as HCM.
Completion of the ﬁnal ﬁltering method (Table 2) indicated that
MYL3 was the only gene that was directly associated with
ventricular myocardium. MYL3 encodes the essential light chain,
an important component of sarcomere, which wraps around the
lever arm of the myosin head, and supports both the neck domain
and the lever arm with myosin regulatory light chain [37]. Previous
reports demonstrate that the loss of MYL3 function causes familial
HCM [38–43]. Olson et al. described HCM patients with the
autosomal recessive MYL3 Glu143Lys variant [38]. These patients
exhibited mid-cavity hypertrophy with restrictive physiology, but in
none of our HCM-subjects was the feature found. Also, Andersen
et al. and Kazmierczak et al. reported the MYL3 Val79Ile and
Ala57Gly variants were causative in HCM [41,43]. In this study, all
subjects with HCM harbored the MYL3 Arg94His variant. Although
the Arg94His was suggested as a potentially causative variant of
sporadic HCM by DNA re-sequencing array [44] or Sanger
sequencing [45], and was also classiﬁed as a ‘‘pathogenic’’ variant
according to the American College of Medical Genetics and
Genomics guideline [46], this is the ﬁrst study to conﬁrm and
support it as a causative variant of HCM by using the co-segregation
pattern in the HCM pedigrees and the unbiased method of WES. In
addition, a detailed description of the clinical phenotype associated
with the MYL3 Arg94His is provided. The myosin light chain belongs
to the EF-hand family of calcium-binding proteins [47]. Therefore,
loss-of EF-hand function may interfere with binding of calcium or
magnesium causing malfunction of myosin kinetics [37], which is
thought to be a potential pathological mechanism of HCM
development [42]. The MYL3 causative variants are primarily
located in exons 3 and 4, which encode the EF-hand 2 domain [37],
and the Arg94 residue is also located in exon 3. Use of the CADD
scaled C-score [22] also predicted this to be a damaging variant site.
The MYL3 Arg94His variant is expected to cause crucial damage to
EF-hand function, myosin kinetics, and its structure, and eventuallyhypertrophic changes in the myocardium, which may underlie the
high disease penetrance and substantial interventricular septal
hypertrophy observed in this study (Table 1). However, due to the
small number of subjects harboring this variant, it remains unclear
whether screening of families with HCM for the MYL3 Arg94His
variant will be useful in patient management. Further study is
needed to clarify the long-term clinical courses in HCM patients with
the MYL3 Arg94His variant.
Study limitations
This study has some limitations. WES was performed with
protein-coding regions only, which potentially overlooked other
intergenic variants that inﬂuenced the speciﬁc phenotype. HCM is
a heterogeneous disorder in terms of both clinical characteristics
and age of onset, limiting the accuracy of the phenotype modeling.
In this study, we could accurately ﬁnd out one causative variant for
HCM, but it might be controversial whether a 48-year-old woman
without apparent HCM phenotype could be classiﬁed as an
unaffected HCM subject. Although CADD enabled more precise
prediction of in silico damaging score than other software, the
optimal cut-off value for detection of deleterious variants with
CADD scaled C-scores is debatable. HHE genes were generated only
by known human-mouse orthologues, which might rule-out
potential human-speciﬁc genes that were highly expressed in
human heart. In addition, clinical information was not available for
some family members, which may have affected the penetrance
and clinical characteristics of HCM with MYL3 Arg94His variant.
Conclusion
Together with CADD score and HHE gene data, WES facilitated
successful identiﬁcation of the one causative variant, the MYL3
Arg94His, even in HCM. Furthermore, the MYL3 Arg94His variant
was associated with high disease penetrance and substantial
ventricular hypertrophy.
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